Literature DB >> 24917112

Increasing nontuberculous mycobacteria infection in cystic fibrosis.

Ophir Bar-On1, Huda Mussaffi2, Meir Mei-Zahav2, Dario Prais2, Guy Steuer1, Patrick Stafler2, Shai Hananya1, Hannah Blau3.   

Abstract

BACKGROUND: Nontuberculous mycobacteria (NTM) are emerging infections in the CF population. AIMS: To assess NTM infection prevalence and associated features in our CF clinic population.
METHODS: Patient records, 2002-2011, were reviewed for NTM infection. FEV1, pancreatic function, sputum microbiology, and serum cytokines were compared in patients with and without NTM infection.
RESULTS: Incidence rate of NTM infection increased from 0 in 2002 to 8.7% in 2011 (p<0.001). NTM infection prevalence increased 3-fold from 5% (4/79) in 2003 to 14.5% (16/110) in 2011 (p=0.05). Prevalence of chronic NTM lung disease has decreased somewhat since a peak in 2009, with institution of aggressive triple therapy. Of NTM-infected compared to uninfected patients, 88.2% vs. 60.3% had a known 'severe' CFTR genotype (p=0.04), 88.2% vs. 58.9% were pancreatic insufficient (p=0.02); 70.6% vs. 43.8% had chronic Pseudomonas aeruginosa (p=0.06); 75% vs. 32% had Aspergillus infection (p=0.007) and 23.5% vs 2.7% had allergic bronchopulmonary aspergillosis (p=0.01). Patients infected with Mycobacterium abscessus had increased TGF-β, TNF-α, IL-1β, IL-2, IL-4 and IL-5 levels (p<0.05). There was no difference in cytokine levels for all NTM infected compared to uninfected patients. M. abscessus comprised 46% of all NTM infections. Comparing M. abscessus versus other NTM, duration was 10.5 (1-118) months versus 1 (1-70) month, median (range) (p=0.004); lung disease occurred in 69% versus 17% (p=0.0004), with sputum conversion in 4/11 versus 5/6, respectively (NS).
CONCLUSIONS: NTM incidence and prevalence have increased dramatically in our CF clinic, associated with a severe CF genotype and phenotype. M. abscessus, the most prevalent NTM, caused prolonged infection despite therapy. There has been some decrease in the prevalence of NTM lung disease since 2009.
Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allergic bronchopulmonary aspergillosis; Cystic fibrosis; Mycobacterium abscessus; Nontuberculous mycobacteria

Mesh:

Year:  2014        PMID: 24917112     DOI: 10.1016/j.jcf.2014.05.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  42 in total

1.  In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus.

Authors:  Eva Le Run; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 2.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

3.  Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.

Authors:  Rongpong Plongla; Clair L Preece; John D Perry; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2017-02-22       Impact factor: 5.948

4.  Evaluation of Various Culture Media for Detection of Rapidly Growing Mycobacteria from Patients with Cystic Fibrosis.

Authors:  Clair L Preece; Thomas A Wichelhaus; Audrey Perry; Amanda L Jones; Stephen P Cummings; John D Perry; Michael Hogardt
Journal:  J Clin Microbiol       Date:  2016-04-20       Impact factor: 5.948

5.  Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models.

Authors:  Andrés Obregón-Henao; Kimberly A Arnett; Marcela Henao-Tamayo; Lisa Massoudi; Elizabeth Creissen; Koen Andries; Anne J Lenaerts; Diane J Ordway
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

6.  Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Rashmi Gupta; Carolina Rodrigues Felix; Matthew P Akerman; Kate J Akerman; Cathryn A Slabber; Wenjie Wang; Jessie Adams; Lindsey N Shaw; Yuk-Ching Tse-Dinh; Orde Q Munro; Kyle H Rohde
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis.

Authors:  Ian Eltringham; Julie Pickering; Helen Gough; Clair L Preece; John D Perry
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

Review 8.  Mycobacterium abscessus Complex Infections in Children: A Review.

Authors:  Arick P Sabin; Patricia Ferrieri; Susan Kline
Journal:  Curr Infect Dis Rep       Date:  2017-10-05       Impact factor: 3.725

9.  In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.

Authors:  Eva Le Run; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 10.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.